<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185197</url>
  </required_header>
  <id_info>
    <org_study_id>Novartis-ST-03</org_study_id>
    <nct_id>NCT01185197</nct_id>
  </id_info>
  <brief_title>Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study</brief_title>
  <official_title>Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objective: To investigate the potential therapeutic efficacy of enteric-coated
      mycophenolate sodium combined with low-dose corticosteroid as first-line treatment for
      minimal change nephrotic syndrome (MCNS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, randomized study in which patients who present for the
      first time with a clinical diagnosis of idiopathic MCNS proven on renal biopsy will be
      assigned to either conventional standard-dose prednisolone monotherapy or myfortic combined
      with low-dose prednisolone treatment for 6 months. Clinical response and relapse rates within
      6 months of treatment cessation will be the main outcome parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission (24 hour urine protein &lt; 0.3 g)</measure>
    <time_frame>at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of cushingoid facies, striae, acne, weight gain, GI disturbance, cytopenia, infection</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nephrosis, Lipoid</condition>
  <arm_group>
    <arm_group_label>Myfortic plus low-dose steroid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Not necessary</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Not necessary</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic plus low-dose steroid</intervention_name>
    <description>Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off</description>
    <arm_group_label>Myfortic plus low-dose steroid</arm_group_label>
    <other_name>Mycophenolate sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician</description>
    <arm_group_label>Standard-dose steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 - 65 years of age

          -  First histologic diagnosis of MCNS

          -  Proteinuria &gt; 3.5 g/day

          -  Patients who are willing to give written, informed consent

        Exclusion Criteria:

          -  Presence of secondary causes of MCNS

          -  History of glomerular disease including MCNS

          -  eGFR &lt; 50 ml/min/1.73m2

          -  Renal histology showing pathologies other than MCNS

          -  Female of child-bearing age who are unwilling to practice effective contraception

          -  Patients simultaneously participating in another study or who have participated in
             another study within the last 30 days of entry into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sydney CW Tang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sydney CW Tang, MD, PhD</last_name>
      <phone>+852-2255 3111</phone>
      <phone_ext>3879</phone_ext>
      <email>scwtang@hku.hk</email>
    </contact>
    <investigator>
      <last_name>Maggie KM Ma, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Desmond YH Yap, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kar Neng Lai, DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>October 25, 2016</last_update_submitted>
  <last_update_submitted_qc>October 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minimal Change Nephrotic Syndrome</keyword>
  <keyword>Corticosteroid</keyword>
  <keyword>Mycophenolate</keyword>
  <keyword>Remission</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

